|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IPPK |
Gene summary for IPPK |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IPPK | Gene ID | 64768 |
| Gene name | inositol-pentakisphosphate 2-kinase | |
| Gene Alias | C9orf12 | |
| Cytomap | 9q22.31 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q9H8X2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64768 | IPPK | CCI_1 | Human | Cervix | CC | 8.18e-06 | 4.98e-01 | 0.528 |
| 64768 | IPPK | CCI_2 | Human | Cervix | CC | 7.87e-09 | 6.87e-01 | 0.5249 |
| 64768 | IPPK | CCI_3 | Human | Cervix | CC | 5.76e-09 | 5.31e-01 | 0.516 |
| 64768 | IPPK | LZE4T | Human | Esophagus | ESCC | 2.12e-06 | 4.28e-02 | 0.0811 |
| 64768 | IPPK | LZE7T | Human | Esophagus | ESCC | 3.46e-03 | 5.74e-02 | 0.0667 |
| 64768 | IPPK | LZE24T | Human | Esophagus | ESCC | 5.54e-11 | 9.95e-02 | 0.0596 |
| 64768 | IPPK | LZE21T | Human | Esophagus | ESCC | 2.28e-02 | 2.46e-01 | 0.0655 |
| 64768 | IPPK | P2T-E | Human | Esophagus | ESCC | 1.96e-19 | 1.45e-01 | 0.1177 |
| 64768 | IPPK | P4T-E | Human | Esophagus | ESCC | 1.11e-11 | 3.70e-02 | 0.1323 |
| 64768 | IPPK | P5T-E | Human | Esophagus | ESCC | 3.26e-11 | 5.24e-02 | 0.1327 |
| 64768 | IPPK | P8T-E | Human | Esophagus | ESCC | 1.10e-04 | -3.87e-02 | 0.0889 |
| 64768 | IPPK | P9T-E | Human | Esophagus | ESCC | 1.50e-13 | 1.58e-01 | 0.1131 |
| 64768 | IPPK | P10T-E | Human | Esophagus | ESCC | 2.03e-06 | -1.43e-02 | 0.116 |
| 64768 | IPPK | P11T-E | Human | Esophagus | ESCC | 1.10e-02 | 3.34e-01 | 0.1426 |
| 64768 | IPPK | P12T-E | Human | Esophagus | ESCC | 2.23e-11 | 2.16e-01 | 0.1122 |
| 64768 | IPPK | P16T-E | Human | Esophagus | ESCC | 4.73e-07 | -3.59e-02 | 0.1153 |
| 64768 | IPPK | P20T-E | Human | Esophagus | ESCC | 1.78e-12 | 3.08e-01 | 0.1124 |
| 64768 | IPPK | P21T-E | Human | Esophagus | ESCC | 7.57e-13 | 3.66e-01 | 0.1617 |
| 64768 | IPPK | P22T-E | Human | Esophagus | ESCC | 1.89e-09 | 2.93e-02 | 0.1236 |
| 64768 | IPPK | P23T-E | Human | Esophagus | ESCC | 1.70e-05 | -1.61e-02 | 0.108 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00987812 | Esophagus | ESCC | ncRNA transcription | 45/8552 | 56/18723 | 1.05e-07 | 1.72e-06 | 45 |
| GO:00063602 | Esophagus | ESCC | transcription by RNA polymerase I | 42/8552 | 55/18723 | 3.41e-06 | 3.78e-05 | 42 |
| GO:00060668 | Esophagus | ESCC | alcohol metabolic process | 202/8552 | 353/18723 | 7.32e-06 | 7.26e-05 | 202 |
| GO:00093032 | Esophagus | ESCC | rRNA transcription | 28/8552 | 34/18723 | 1.21e-05 | 1.12e-04 | 28 |
| GO:00063564 | Esophagus | ESCC | regulation of transcription by RNA polymerase I | 27/8552 | 34/18723 | 6.01e-05 | 4.62e-04 | 27 |
| GO:00442626 | Esophagus | ESCC | cellular carbohydrate metabolic process | 160/8552 | 283/18723 | 1.43e-04 | 9.66e-04 | 160 |
| GO:00459432 | Esophagus | ESCC | positive regulation of transcription by RNA polymerase I | 19/8552 | 23/18723 | 3.12e-04 | 1.85e-03 | 19 |
| GO:00461653 | Esophagus | ESCC | alcohol biosynthetic process | 83/8552 | 140/18723 | 8.04e-04 | 4.16e-03 | 83 |
| GO:00427902 | Esophagus | ESCC | nucleolar large rRNA transcription by RNA polymerase I | 15/8552 | 18/18723 | 1.20e-03 | 5.88e-03 | 15 |
| GO:19018381 | Esophagus | ESCC | positive regulation of transcription of nucleolar large rRNA by RNA polymerase I | 9/8552 | 10/18723 | 5.09e-03 | 1.92e-02 | 9 |
| GO:19016174 | Esophagus | ESCC | organic hydroxy compound biosynthetic process | 128/8552 | 237/18723 | 5.86e-03 | 2.16e-02 | 128 |
| GO:19018361 | Esophagus | ESCC | regulation of transcription of nucleolar large rRNA by RNA polymerase I | 12/8552 | 15/18723 | 7.31e-03 | 2.63e-02 | 12 |
| GO:00060667 | Oral cavity | OSCC | alcohol metabolic process | 179/7305 | 353/18723 | 4.54e-06 | 5.21e-05 | 179 |
| GO:00987811 | Oral cavity | OSCC | ncRNA transcription | 38/7305 | 56/18723 | 1.15e-05 | 1.18e-04 | 38 |
| GO:00063563 | Oral cavity | OSCC | regulation of transcription by RNA polymerase I | 25/7305 | 34/18723 | 4.63e-05 | 3.90e-04 | 25 |
| GO:00063601 | Oral cavity | OSCC | transcription by RNA polymerase I | 36/7305 | 55/18723 | 6.42e-05 | 5.22e-04 | 36 |
| GO:00461652 | Oral cavity | OSCC | alcohol biosynthetic process | 77/7305 | 140/18723 | 8.77e-05 | 6.70e-04 | 77 |
| GO:00459431 | Oral cavity | OSCC | positive regulation of transcription by RNA polymerase I | 18/7305 | 23/18723 | 1.47e-04 | 1.04e-03 | 18 |
| GO:00093031 | Oral cavity | OSCC | rRNA transcription | 24/7305 | 34/18723 | 1.89e-04 | 1.28e-03 | 24 |
| GO:00427901 | Oral cavity | OSCC | nucleolar large rRNA transcription by RNA polymerase I | 14/7305 | 18/18723 | 9.51e-04 | 4.96e-03 | 14 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IPPK | SNV | Missense_Mutation | rs200546991 | c.1005C>G | p.Ile335Met | p.I335M | Q9H8X2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| IPPK | SNV | Missense_Mutation | novel | c.784G>A | p.Val262Met | p.V262M | Q9H8X2 | protein_coding | deleterious(0) | possibly_damaging(0.776) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
| IPPK | SNV | Missense_Mutation | novel | c.1135N>A | p.Glu379Lys | p.E379K | Q9H8X2 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-Z7-A8R6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
| IPPK | deletion | Frame_Shift_Del | novel | c.1028delA | p.Asn343ThrfsTer19 | p.N343Tfs*19 | Q9H8X2 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| IPPK | deletion | Frame_Shift_Del | novel | c.21delC | p.Asp7GlufsTer29 | p.D7Efs*29 | Q9H8X2 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| IPPK | SNV | Missense_Mutation | novel | c.1031N>A | p.Arg344Gln | p.R344Q | Q9H8X2 | protein_coding | tolerated(0.08) | possibly_damaging(0.542) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| IPPK | SNV | Missense_Mutation | novel | c.384N>T | p.Glu128Asp | p.E128D | Q9H8X2 | protein_coding | tolerated(0.16) | benign(0.034) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| IPPK | SNV | Missense_Mutation | rs150868938 | c.800N>A | p.Arg267Gln | p.R267Q | Q9H8X2 | protein_coding | tolerated(0.58) | benign(0.119) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| IPPK | SNV | Missense_Mutation | c.139N>A | p.Glu47Lys | p.E47K | Q9H8X2 | protein_coding | tolerated(0.25) | possibly_damaging(0.621) | TCGA-R2-A69V-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| IPPK | SNV | Missense_Mutation | c.97C>T | p.Arg33Trp | p.R33W | Q9H8X2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |